A5007279449- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- 2D Materials and Applications
- HER2/EGFR in Cancer Research
- Metal and Thin Film Mechanics
- MXene and MAX Phase Materials
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- ZnO doping and properties
- Hepatocellular Carcinoma Treatment and Prognosis
- Occupational and environmental lung diseases
- Gas Sensing Nanomaterials and Sensors
- Neuroblastoma Research and Treatments
- Cancer Treatment and Pharmacology
- Semiconductor materials and interfaces
- Neonatal Respiratory Health Research
- Peptidase Inhibition and Analysis
- RNA modifications and cancer
- Palliative Care and End-of-Life Issues
- Childhood Cancer Survivors' Quality of Life
Aichi Cancer Center
2016-2025
University of the Arts London
2023
Tokyo Health Care University
2022
Japanese Red Cross Nagoya Daini Hospital
2021
NTT Medical Center
2021
Tokyo Institute of Technology
2016-2018
ORCID
2018
The University of Tokyo
1977-2017
Oregon Health & Science University
2017
Tokyo Metropolitan University
2007-2017
Anaplastic lymphoma kinase (ALK) rearrangement-positive non-small-cell lung cancers can be effectively treated with an ALK tyrosine inhibitor (TKI) such as crizotinib, but the response magnitude and duration are heterogeneous. Several variants have been identified, few studies focused on effects of different efficacy crizotinib.Among 55 patients crizotinib initial ALK-TKI between January 2007 December 2014, we identified 35 tumor specimens that could evaluated for by reverse transcription...
Although treatment with first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) plus antiangiogenic has shown promising efficacies in patients EGFR-mutated lung adenocarcinoma, recent single-arm studies have suggested that osimertinib might not work synergistically.To explore the efficacy and safety of bevacizumab compared alone adenocarcinoma EGFR T790M mutation.Patients advanced progressed prior EGFR-TKI (other than third-generation TKI) acquired mutation...
Trastuzumab deruxtecan (T-DXd) 5.4 and 6.4 mg/kg showed robust antitumor activity in multiple cancer indications; however, T-DXd has not been evaluated patients with previously treated human epidermal growth factor receptor 2-mutant (
PURPOSE Datopotamab deruxtecan (Dato-DXd) is a trophoblast cell-surface antigen-2–directed antibody-drug conjugate with highly potent topoisomerase I inhibitor payload. The TROPION-Lung05 phase II trial (ClinicalTrials.gov identifier: NCT04484142 ) evaluated the safety and clinical activity of Dato-DXd in patients advanced/metastatic non–small cell lung cancer (NSCLC) actionable genomic alterations progressing on or after targeted therapy platinum-based chemotherapy. PATIENTS AND METHODS...
Abstract Purpose: The vast majority of epidermal growth factor receptor (EGFR) mutations occur in lung adenocarcinoma, and even rare cases other subtypes with this mutation, such as adenosquamous cell carcinoma, are associated adenocarcinoma histology. According to adenocarcinoma-specific nature EGFR analysis small cancers (SCLC) may provide a clue its histogenesis. Experimental Design: mutational status the gene was accessed cohort 122 patients SCLC; all were from single institute. When...
Nivolumab offers a superior survival benefit over docetaxel in patients with advanced, previously treated non-small-cell lung cancer (NSCLC). An association between programmed cell death ligand-1 (PD-L1) expression and the efficacy of nivolumab has been reported many studies. However, clinical parameters remains unclear advanced NSCLC patients.Among 124 patients, 108 (88%) were performance status (PS) 0 to 1. PD-L1 was assessed 89 51 (57%) having positive expression. In all objective...
In the resected lung, additional small lesions are occasionally found incidentally, and include full spectrum of preinvasive to invasive under current putative schema sequential development lung cancer. this study, we examined EGFR KRAS gene mutations in 119 synchronous pulmonary lesions, including 40 precursor (atypical adenomatous hyperplasia, AAH), 26 carcinomas situ (non-mucinous bronchioloalveolar carcinoma, BAC), 14 minimally adenocarcinomas, 34 overt five other subtypes Although...
ObjectivesTo describe the treatment patterns and determine effectiveness safety of nivolumab for non-small cell lung cancer (NSCLC) in real-world setting Japan.Materials methodsJapanese patients with NSCLC who received were analyzed retrospectively. Patients had started between April 2016 December enrolled. Information regarding patient demographics clinical backgrounds, from diagnosis to post-nivolumab treatment, that treatments just before after programmed death-ligand 1 (PD-L1) expression...
Background Studies have suggested that chemotherapy after immune checkpoint inhibitors may confer an improved response for non–small cell lung cancer (NSCLC). However, potential selection bias in such studies has not been addressed. We therefore applied propensity score analysis to investigate the efficacy of PD-1 inhibitor treatment (CAP) compared with alone. Methods conducted a retrospective observational cohort study patients treated at 47 institutions across Japan between April 1, 2014...
BACKGROUND Lung adenocarcinoma in the young is a rare entity, and oncogenic genetic alterations (GAs) clinical characteristics associated with this disease are poorly understood. Conversely, it has been demonstrated that age at diagnosis defines unique biology other cancers. For report, effects of on lung reported. METHODS The authors retrospectively screened 1746 consecutive patients who were diagnosed stage I through IV between 2009 2015 identified 81 aged 40 years or younger diagnosis....
A three-item sense of coherence (SOC) scale was developed, incorporating the definitions three subordinate concepts SOC for use in population surveys. cross-sectional internet survey conducted latter part July 2006. Cronbach's alpha 0.84. The correlation coefficient SOC-13 and newly devised University Tokyo Health Sociology version Scale (SOC-3-UTHS) 0.51. As regards with a health index, SOC-3-UTHS had significant association, although this association somewhat weaker than that SOC-13....
The aim of this study was to evaluate the efficacy and indication combination therapy with ribavirin plus peginterferon-alpha-2b in chronic hepatitis C virus (HCV) patients aged 65 years older.Five hundred ninety-one consecutive HCV were treated therapy. These divided into elder (> or = years) (n=115) younger (< (n=476). clinical characteristics, sustained virological response (SVR) rates discontinuation compared between two groups.Compared patients, baseline haemoglobin levels platelet...
Abstract Immune checkpoint inhibitors (ICIs) have dramatically changed the strategy used to treat patients with non‐small‐cell lung cancer (NSCLC); however, vast majority of eventually develop progressive disease (PD) and acquire resistance ICIs. Some experience oligoprogressive disease. Few retrospective studies evaluated clinical efficacy in oligometastatic progression who received local therapy after ICI treatment. We conducted a analysis advanced NSCLC PD‐1 inhibitor monotherapy...
IntroductionAbout 10% of patients with locally advanced NSCLC (LA-NSCLC) harbor EGFR mutation and recent reports suggested the declined benefit an immune checkpoint inhibitor in this population. The attempt that introduces tyrosine kinase into treatment LA-NSCLC has been warranted.MethodsChemotherapy-naive unresectable sensitive (exon 19 deletion or exon 21 L858R point mutation) were enrolled. Patients treated gefitinib (250 mg/d for 2 y) plus concurrent thoracic radiotherapy (64 Gy/32...
Abstract: Aim: We investigated pathological features of Lens culinaris agglutinin‐reactive α‐fetoprotein (AFP‐L3)‐positive hepatocellular carcinoma (HCC) in order to seek a basis poor prognosis HCC patients with elevated AFP‐L3. Methods: A total 111 ≤5 cm diameter who underwent hepatic resection were studied. Serum AFP‐L3 concentration was measured within month prior surgery by lectin‐affinity electrophoresis coupled antibody‐affinity blotting, and expressed as percentage AFP. 10% or higher...